anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to heatstroke preventing tea which belongs to the field of human drinking tea. The heatstroke preventing tea is prepared by mixing Chinese medicinal plants of ophiopogon root, radix adenophorae, schisandra fruit, honeysuckle flower, peppermint, balloonflower root, dendrobium, dry Chinese white olive, boat-fruited sterculia, hawthorn fruit, lalang grass rhizome, common lophatherum herb and licorice root. The heatstroke preventing tea has the obvious efficacy of nourishing yin, clearing heat evil, promoting the production of saliva, moistening throat, eliminating dampness and heat, benefiting qi, quenching thirst and preventing heatstroke. The heatstroke preventing tea can replenish loss of organic constituents, such as water, citric acid, glucose, vitamins, etc., caused by excessive sweating under a hot environment in time. The heatstroke preventing tea has the characteristics of cool, throat moistening, favorable sour-sweet taste, no toxic or side effect, long storage time, etc. The heatstroke preventing tea is prepared in the form of bag tea, and heatstroke can be prevented by drinking water daily. The present invention has the advantages of portability, sanitation, convenience for drinking, repeated soaking, etc., and can be drunk in cold and hot.
BACKGROUND: Persistent somatic symptoms (PSS) frequently remain under-treated in health care settings. Evidence-based services that lead affected individuals to early guideline-based care are currently missing. This study aimed to identify the needs of those affected concerning an internet-based guide. The second aim was to evaluate public and patient involvement (PPI).
METHODS: Participants experiencing PSS for at least 6 months were recruited via hospitals, psychotherapeutic practices and self-help organizations. Qualitative data were gathered via ideation discussions and prioritization tasks. Thematic analysis was conducted to gain insight on the needs of people with lived experiences. PPI was quantitatively evaluated with the Public and Patient Engagement Evaluation Tool.
RESULTS: A total of 12 individuals participated (eight females, ages 22-66 years, duration of symptoms 1-43 years). Participants wanted to feel more supported, validated, in control and engaged with managing their health. Content-related preferences included education, self-help, social support and contact addresses. The majority of participants (>90%) experienced their involvement as worthwhile.
CONCLUSIONS: To the best of our knowledge, this is one of the first studies describing PPI in intervention development for PSS. The involvement was perceived as a valuable contribution to the development process.
PATIENT OR PUBLIC CONTRIBUTION: Adults with lived experiences were involved at the level of collaboration through the establishment of a participatory research team (PRT) and at the level of consultation through a workshop series, including one of the coauthors. They were involved in developing and validating intervention material and checking data interpretation.
Participants randomized to intervention will undergo booster training sessions with the RQI cart (including audiovisual feedback) at 3, 6 and 9 months post instructor-led training session. Following each of these booster sessions, the participants will undergo 1 minute assessments, without feedback.
<P>PROBLEM TO BE SOLVED: To provide a new melanoma treatment.  <P>SOLUTION: The composition comprises a peptide which stimulates an antibody response to a high molecular weight melanoma-associated antigen (HMW-MAA). The method for stimulating an immune response to a HMW-MAA comprises using the peptide. The peptide is designed from a structure between a HMW-MAA and mouse-anti-idiotypic monoclonal antibody MK2-23 and identification of domain of amino acid sequence homology. The method comprises a step for administering one or more kinds of the peptides in an amount effective for inducing an immune response to a HMW-MAA to an individual.  <P>COPYRIGHT: (C)2007,JPO&INPIT
In the study arm, subjects will receive PCV13, DTaP and IIV vaccines during visit 1. Approximately 2 weeks later, subjects will receive a health education visit without vaccination during study visit 2.
Iohexol is absorbed from cerebrospinal fluid (CSF) into the bloodstream and is eliminated by renal excretion. No significant metabolism, deiodination, or biotransformation occurs.

The initial concentration and volume of the medium, in conjunction with appropriate patient manipulation and the volume of CSF into which the medium is placed, will determine the extent of the diagnostic contrast that can be achieved.

Following intrathecal injection in conventional radiography, OMNIPAQUE 300 will continue to provide good diagnostic contrast for at least 30 minutes. Slow diffusion of iohexol takes place throughout the CSF with subsequent absorption into the bloodstream. Once in the systemic circulation, iohexol displays little tendency to bind to serum or plasma proteins. At approximately 1 hour following injection, contrast of diagnostic quality will no longer be available for conventional myelography. If computerized tomographic (CT) myelography is to follow, consideration should be given to a delay of several hours to allow the degree of contrast to decrease.

After administration into the lumbar subarachnoid space, computerized tomography shows the presence of contrast medium in the thoracic region in about 1 hour, in the cervical region in about 2 hours, and in the basal cisterns in 3 to 4 hours.

In patients with renal impairment, depending on the degree of impairment, prolonged plasma iohexol levels may be anticipated due to decreased renal elimination.
Systems and methods can support managing clinical alerts presented to clinical care users. An integration management system can maintain models of clinical alert events in the context of user behaviors and in the context of patients. Alarm indications associated with the patient may be received along with context information associated with the patient. Patient information may be received from an electronic medical record system. Integrated decision processing can integrate two or more of the alarm indication, the models of clinical alert events, the patient context, and the information from the electronic medical record system. The integrated decision processing can determine if a clinical alert is to be generated, what type, and to whom. The clinical alert can be transmitted to a target user. A response can be received and interpreted. Information associated with the patient may be updated into the electronic medical record system.
Streptococcus suis (S. suis) disease is a prevalent zoonotic infectious threat that elicits a systemic inflammatory response in both swine and humans, frequently culminating in high mortality rates. The excessive inflammation triggered by S. suis infection can precipitate tissue damage and sudden death; however, a comprehensive strategy to mitigate this inflammatory response remains elusive. Our study examines the role of NLRP6 in S. suis infection, with a particular focus on its involvement in pathogen regulation. A marked upregulation of NLRP6 was observed in peritoneal macrophages post-infection with S. suis SC19 strain, consequently activating the NLRP6 inflammasome. Furthermore, SC19 infection was found to augment the secretion of pro-inflammatory cytokines IL-1β via NLRP6 activation, while NLRP6 deficiency mitigates the invasion and adhesion of SC19 to macrophages. In vivo models revealed that NLRP6 deletion enhanced survival rates of SC19-infected mice, alongside a reduction in tissue bacterial load and inflammatory cytokine levels. NLRP6-/- mice were shown to exhibit attenuated inflammatory responses in pulmonary, hepatic, and splenic tissues post-SC19 infection, as evidenced by lower inflammation scores. Flow cytometry analyses further substantiated that NLRP6 is involved in modulating macrophage and neutrophil recruitment during infection. Our findings suggest that NLRP6 negatively regulates host resistance against S. suis infection; its absence results in reduced mortality, bacterial colonization, and a milder inflammatory response. Elucidating the mechanism of NLRP6 in S. suis-induced inflammation provides novel insights and theoretical underpinnings for the prophylaxis and therapeutics of S. suis diseases.
EDP will be administered at the following doses: doxorubicin 40 mg/m2 on day 1, etoposide 100 mg/m2 days 2-4, cisplatin 40 mg/m2 days 3-4, every 28 days. Concomitant mitotane therapy will be administered continuously. Placebo 2 tablets will be administered once daily (in the morning) and will be stopped 21 days after the last administration of the EDP.
Provided are a class of compounds, a stereoisomer, an optical isomer, a pharmaceutically acceptable salt, a prodrug, a solvate (for example, a hydrate) or an isotope derivative thereof. The compounds have a tri-heterocyclic structure (for example, the structure represented by formula (A)), which is a novel structure, thereby providing a new direction for the development of SOS1 inhibitor drugs. In-vitro enzyme activity inhibition activity studies show that the compounds have a relatively strong inhibition effect on SOS1 and can be used as a prospective compound for preventing and/or treating SOS1-mediated diseases. Moreover, said compounds also exhibit significant inhibitory activity on NCI-H358 cell proliferation. Furthermore, a specific synthesis method is provided. The synthesis method is simple in process, convenient to operate and beneficial to large-scale industrial production and use.
Primary progressive aphasia (PPA) is a disease known to affect the frontal and temporal regions of the left hemisphere. PPA is often an indication of future development of dementia, specifically semantic dementia (SD) for frontotemporal dementia (FTD) and logopenic progressive aphasia (LPA) as an atypical presentation of Alzheimer's disease (AD). The purpose of this review is to clarify the value of 2-deoxy-2-[18F]fluoro-D-glucose (FDG)-positron emission tomography (PET) in the detection and diagnosis of PPA. A comprehensive review of literature was conducted using Web of Science, PubMed, and Google Scholar. The three PPA subtypes show distinct regions of hypometabolism in FDG-PET imaging with SD in the anterior temporal lobes, LPA in the left temporo-parietal junction, and nonfluent/agrammatic Variant PPA (nfvPPA) in the left inferior frontal gyrus and insula. Despite the distinct patterns, overlapping hypometabolic areas can complicate differential diagnosis, especially in patients with SD who are frequently diagnosed with AD. Integration with other diagnostic tools could refine the diagnostic process and lead to improved patient outcomes. Future research should focus on validating these findings in larger populations and exploring the therapeutic implications of early, accurate PPA diagnosis with more targeted therapeutic interventions.
The present invention discloses a medicinal composition for removing fire and nourishing yin, which comprises aloe, panax pseudo-ginseng, red sage root, imperatae rhizoma, pseudostellaria root, heartleaf houttuynia herb, phoenix-tail fern and liquorice. Through clinical verification, the prevention rate reaches 100%, and the treatment effective rate reaches 90%. The present invention is specific medicine for treating symptom of heat source, and simultaneously, the present invention also has preferable curative effects on disease symptoms of diabetes, hyperlipemia, headache, spondylalgia, prolapse of intervertebral disk, neuralgia, gastric hemorrhage, gynecology inflammation, etc. and various stubborn diseases. The present invention can be used for cleaning blood, expediting the channel and circulating systems. The present invention which is suitable for men, women, the young and the old has the advantages of obvious effect, safety, no side effect, stable curative effect, and prevention and treatment of whole body. The present invention can be used for removing disease evil and cause of disease, regulating and recovering physiological functions of a body, and reinforcing the ability for resisting diseases. The present invention is the pure Chinese medicine which has dual efficiency of treating disease and health care.
FIELD: medicine, dermatology. SUBSTANCE: invention describes application of one or more acid alkylfumarates of the general formula (I):   where R means C 1 -C 5 -alkyl mixed if necessary with dialkyl-fumarates of the formula (II):   and, possibly, with conventional pharmaceutical accessory agents and carriers for preparing pharmaceutical preparative form as microtablets or microgranules. Proposed acid fumarates are used for treatment of psoriasis, psoriatic arthritis, neurodermitis and chronic cicatrizing enteritis. Microtablets and microgranules are distributed in stomach uniformly. EFFECT: improved and valuable medicinal properties of compounds. 7 cl, 2 tbl, 1 ex
Patients receive cyclophosphamide IV QD over 30 minutes and etoposide IV QD over 60 minutes on days 1-5 in the absence of unacceptable toxicity. Patients then receive cord blood derived allogeneic NK cells IV on day 8.
OBJECTIVE: Pain and cognitive impairment are prevalent and often co-occur in older adults. Because pain may negatively affect cognitive test performance, identification of pain in the context of neuropsychological evaluation is important. However, pain detection based on self-report presents challenges, and pain is often under-detected in this population. Alternative methods (e.g., video-based automatic coding of facial biomarkers of pain) may facilitate pain identification and thus enhance interpretation of neuropsychological evaluation results.
METHOD: The current study examined pain in the context of virtual neuropsychological assessment in 111 community-dwelling older adults, first seeking to validate the use of software developed to automatically code biomarkers of pain. Measures of pain, including self-report of acute and chronic pain and automatic coding of pain, were compared while participants completed neuropsychological testing.
RESULTS: Self-reported pain was negatively associated with poorer performance on a measure of executive function (both acute and chronic pain) and a global cognitive screening measure (acute pain only). However, self-reported acute and chronic pain did not correlate significantly with most neuropsychological tests. Automatic coding of pain did not predict self-report of pain or performance on neuropsychological tests beyond the influence of demographic factors and psychological symptoms.
CONCLUSIONS: Though results were largely not significant, correlations warrant further exploration of the influence of pain on neuropsychological test performance in this context to ensure that pain does not influence test performance in individuals with higher levels of pain and in other samples.
Previous studies have shown that epigenetic factors are involved in the occurrence and development of rheumatoid arthritis (RA). However, the role of N6-methyladenosine (m6A) methylation in RA has not been determined. The aim of this study was to investigate the role and regulatory mechanisms of hypoxia-induced expression of the m6A demethylase alkB homolog 5 (ALKBH5) in RA fibroblast-like synoviocytes (FLSs). Synovial tissues were collected from RA and osteoarthritis (OA) patients, and RA FLSs were obtained. ALKBH5 expression in RA FLSs and collagen-induced arthritis (CIA) model rats was determined using quantitative reverse transcription-PCR (qRT-PCR), western blotting and immunohistochemistry (IHC). Using ALKBH5 overexpression and knockdown, we determined the role of ALKBH5 in RA FLS aggression and inflammation. The role of ALKBH5 in RA FLS regulation was explored using m6A-methylated RNA sequencing and methylated RNA immunoprecipitation coupled with quantitative real-time PCR. The expression of ALKBH5 was increased in RA synovial tissues, CIA model rats and RA FLSs, and a hypoxic environment increased the expression of ALKBH5 in FLSs. Increased expression of ALKBH5 promoted the proliferation and migration of RA-FLSs and inflammation. Conversely, decreased ALKBH5 expression inhibited the migration of RA-FLSs and inflammation. Mechanistically, hypoxia-induced ALKBH5 expression promoted FLS aggression and inflammation by regulating CH25H mRNA stability. Our study elucidated the functional roles of ALKBH5 and mRNA m6A methylation in RA and revealed that the HIF1α/2α-ALKBH5-CH25H pathway may be key for FLS aggression and inflammation. This study provides a novel approach for the treatment of RA by targeting the HIF1α/2α-ALKBH5-CH25H pathway.
Through experimental design and quantitative research methods. In this experiment, the resistance training method of water combined with land was used to intervene the turning and starting of young people, and the traditional strength training was compared to find out a better training method. The experiment will use 12 weeks of resistance training to improve the swimmer's turn and start intervention. The experiment consisted of four groups, 20 boys and 20 girls in the experimental group and 20 boys and 20 girls in the control group. Compare the differences between the two groups. Divided into discussion groups and general teaching groups. Two of the most significant differences, this experiment aims to provide a theoretical basis for improving the training methods of swimming, so that young swimmers can get better swimming performance, especially on the start and turn.

Experiment Group Week1-3: Drag Umbrella , Resistance Bands, Swiss Ball, Hand Resistance. Week3-6: Drag Umbrella , Resistance Bands, Swiss Ball, Hand Resistance. Week6-9: Drag Umbrella, Pulley Pull, Medicine Ball, Resistance Suit. Week9-12: Drag Umbrella Pulley Pull, Medicine Ball, Resistance Suit. Control Group Week1-3: Sit-Up, Press-Up, Deep Squat, Lift Heel Week 3-6: Sit-Up, Press-Up, Deep Squat, Lift Heel Week6-9: Dumbbell, Barbell ,Stomach Up, Squat Up Week9-12: Dumbbell, Barbell, Stomach Up, Squat Up
PURPOSE: A pharmaceutical composition which prevents and treats arthritis is provided to continuously treat arthritis without side effects. CONSTITUTION: A pharmaceutical composition which prevents and treating arthritis contains beta-1,3-1,6 branched D-glucan. The beta-1,3-1,6 branched D-glucan has chemical formula I. The administration amount of the pharmaceutical composition is 21.25mg/kg to 85mg/kg. A therapeutic agent for arthritis contains the pharmaceutical composition. A therapeutic agent for rheumatoid arthritis and heath supplement also contains the pharmaceutical composition.
PURPOSE: To obtain an analgesic and vasodilator agent consisting of a partially novel deriv. obtd. by modifying the chemical structure of capsaicin having high solubility in a weakly alkaline aq. soln.  
     CONSTITUTION: An analgesic and vasodilator agent consisting of the capsaicin deriv. or its acid ester, more particularly a capsaicin deriv. of formula I [R 1  is carboxyl, an acyl [R' 1 CO-(R' 1  is an alkyl)]; R 2  is H, an alkyl, CO(CH 2 ) n COOH [(n) is 1 to 5) and above all, a novel capsaicin deriv. of formula II. The compd. of formula I is obtd. by collecting, for example, a nonanoylvanilly lamide of formula III by alkalization of an org. solvent layer formed by bringing a hydrophilic group into an addition reaction at 10 to 100°C in the presence of a suitable catalyst, adding an org. solvent to the reaction product and washing the product with water after stirring, then filtering the same. 
     COPYRIGHT: (C)1992,JPO
Disorders of sex development (DSD) are a wide range of congenital conditions characterized by incongruent development of the components involved in sex differentiation including chromosomes, gonads, brain and anatomic sex.Sex assignment is a critical aspect in management of DSD and it is determined by investigations, genital appearance, fertility potential and cultural practices and pressurs. It is recommended that genital surgery for a child raised as a female considered only in cases of severe virilization (Prader 3-5) and that surgery for the clitoris not be performed for reasons of cosmesis only.Feminizing genital reconstruction has evolved considerably over the past decades as a result of improved understanding of anatomy , modification of surgical procedures and audit of outcomes. For patients with congenital adrenal hyperplasia (CAH) with severe virilization raised as a female , it is recommended that clitorial and perineal reconstruction be considered in infancy and those with a low vaginal confluence undergo vaginoplasty at an early age , the appropriate timing for those with higher vaginal confluence is still less certain. Cosmetic outcomes after genitoplasty are variable. Most studies have detected only functional and cosmetic outcomes rated by the physician, but satisfaction ratings may differ between physicians and patients or their parents . The present prospective , interventional study aimed to describe the frequency of sex assignment and types of surgery performed in a cohort of patients with moderate to severe genital ambiguity and also evaluate surgical outcomes of feminizing genitoplasty in these patients .
XENICAL may interact with concomitant drugs including cyclosporine, levothyroxine, warfarin, amiodarone, antiepileptic drugs, and antiretroviral drugs [see Drug Interactions (7)]. 

Data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine. Therefore, XENICAL and cyclosporine should not be simultaneously coadministered. To reduce the chance of a drug-drug interaction, cyclosporine should be taken at least 3 hours before or after XENICAL in patients taking both drugs. In addition, in those patients whose cyclosporine levels are being measured, more frequent monitoring should be considered.

Patients should be strongly encouraged to take a multivitamin supplement that contains fat-soluble vitamins to ensure adequate nutrition because XENICAL has been shown to reduce the absorption of some fat-soluble vitamins and beta-carotene [see  Dosage and Administration (2), and Adverse Reactions (6.1)] . In addition, the levels of vitamin D and beta-carotene may be low in obese patients compared with non-obese subjects. The supplement should be taken once a day at least 2 hours before or after the administration of XENICAL, such as at bedtime. 

Weight-loss may affect glycemic control in patients with diabetes mellitus. A reduction in dose of oral hypoglycemic medication (e.g., sulfonylureas) or insulin may be required in some patients [see  Clinical Studies (14)] .
Patients receive placebo PO BID on days 1-7. Patients also receive paclitaxel and carboplatin as in Phase I. Treatment repeats every 3 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. Within 10 days from completion of course 2, patients begin concomitant chemoradiotherapy.
Clavamox, Film-coated Tablets, 875 mg + 125 mg, is the test product. 14 of 28 subjects in each of two cohorts (total number of enrolled volunteers - 56) were given a single tablet (containing 875 mg mg of amoxicillin and 125 mg of clavulanic acid) in period 1 and period 2 of the clinical part of the study.
Placement of OxyChip will be through a minimally invasive procedure (needle injection) and removal will be at the time of surgical resection. In Phase IA, patients will not have any cancer therapy prior to removal of the OxyChip and duration of implantation is typically less than 4 weeks but may be up to 52 weeks.